Tag: Novo Nordisk Canada
-
Canada Welcomes Sogroya: The First Weekly Growth Hormone Therapy for GHD
Canada Launches Sogroya as the First Weekly Growth Hormone Therapy for GHD Canada has welcomed Sogroya® (somapacitan injection) as a new, once-weekly option for children and adults living with growth hormone deficiency (GHD). This landmark approval marks the first and only regimen of its kind that reduces the frequency of injections while delivering effective growth…
-
Province commits $2M to fight chronic diseases
Alberta launches a targeted push against chronic diseases The Alberta government has committed $2 million to the Alberta Lighthouse Initiative, a joint effort designed to fund projects focused on managing chronic diseases such as Type 2 diabetes, obesity, and heart disease. The province partners with Novo Nordisk Canada, which is contributing $2 million, and Alberta…